Article
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
AIDS research and human retroviruses - 1 Aug 2018
Diphoko Thabo, Gaseitsiwe Simani, Kasvosve Ishmael, Moyo Sikhulile, Okatch Harriet, Musonda Rosemary, Wainberg Mark, Makhema Joseph, Marlink Richard, Novitsky Vladimir, Essex Max
Abstract excerpt
Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. There is a cross-resistance HIV mutation profile between first- and second-generation NNRTI drugs. We determined the prevalence of HIV-1 drug resistance mutations (DRMs) to RPV and ETR in Botswana. A total of 168 HIV-1 polymerase gene sequences from participants failing...
Topics
Join the communities discussing this publication.